Wed, 15 Oct 2025 | BUSINESS NEWS
Bedfont Scientific, a Kent-based designer and manufacturer of non-invasive breath analysis devices, is set to target M&A and organic growth after a Paris-based growth buyout investor acquired a controlling stake in the firm.
Founded in 1976, Bedfont Scientific develops high precision breath and gas analysis devices. The company is particularly focused on the NObreath device for FeNO testing, which is a key biomarker for asthma diagnosis and management.
The Maidstone-based company’s portfolio also includes solutions for smoking cessation and hydrogen and methane breath testing for gastrointestinal disorders. The firm’s products are distributed via a network of over 100 partners in more than 70 countries.
Bedfont Scientific has now secured backing from Keensight Capital, a growth buyout investor with previous investments in medtech and respiratory device businesses. Keensight will work with the company’s management to accelerate the growth and international expansion of the business, both organically and through M&A.
Bedfont Scientific Chief Executive Jason Smith stated that the company sees “significant opportunity to expand the use of breath analysis in medical diagnosis and monitoring.”
He added that it was critical for such technology to be both reliable and accessible and that Keensight’s support would enable Bedfont “to increase patient outreach and improve patient access worldwide."
Keensight Capital partner Amit Karna added: "Bedfont is a highly innovative company whose pioneering work in breath biomarkers, particularly FeNO, is helping to advance global standards in respiratory diagnostics.”
In accounts for the year to September 30 2024, Bedfont Scientific Limited reported turnover of £9.4 million, down slightly from £9.6 million a year earlier, while operating profit dipped from around £2.2 million to just under £1.6 million.
However, directors stated at the time that “the company’s financial position remains strong, with steady profitability, solid IP protection and recurring demand through global distribution.”
Rapid technological advancement and private equity investment are among the key factors driving M&A in the UK medtech space
This highly profitable independent dispensing pharmacy in Birmingham boasts a prime suburban location, filling approximately 10,000 prescriptions monthly.
LEASEHOLD
This well-established domiciliary care business in Cambridgeshire has demonstrated strong year-on-year revenue growth since its inception in 2018.
This well-established social care company, situated in Yorkshire, boasts eight owned supported living properties and has secured contracts with local authorities, ensuring a steady stream of revenue.
Please choose your settings for this site below. For more information please read our Cookie Policy
These cookies are necessary for our website to function properly and provide you with access to all features.
These are analytics cookies that help us to improve the way our website works.
These are used to improve the functional performance of the website and make it easier for you to use.